Last $1.15 USD
Change Today +0.0017 / 0.15%
Volume 21.5K
OGEN On Other Exchanges
As of 8:04 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

oragenics inc (OGEN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/3/14 - $3.87
52 Week Low
02/5/15 - $0.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ORAGENICS INC (OGEN)

Related News

No related news articles were found.

oragenics inc (OGEN) Related Businessweek News

No Related Businessweek News Found

oragenics inc (OGEN) Details

Oragenics, Inc. focuses on the discovery, development, and commercialization of various technologies associated with oral health, antibiotics, and other general health benefits. It develops and markets probiotic products comprising ProBiora3, an oral care probiotics that promote oral health for humans and pets under the Evora and ProBiora brands in approximately 13 countries worldwide. The company’s ProBiora3 products include flavored probiotic tablets, such as EvoraPlus and EvoraKids for daily use by adults and children; EvoraPet for companion pets, including cats and dogs; and EvoraPro, a product for the dental office channel. Its product candidates consists of LPT3-04, a naturally occurring compound for weight loss; SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay; and MU1140-S, an antibiotic product candidate in preclinical testing for healthcare-associated infections. Oragenics, Inc. offers its ProBiora3 products through direct-to-consumer channels, professional offices, and private label partnerships. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.

9 Employees
Last Reported Date: 02/28/14
Founded in 1996

oragenics inc (OGEN) Top Compensated Officers

Interim Principal Executive Officer, Chief Fi...
Total Annual Compensation: $200.8K
Senior Vice President of Discovery Research
Total Annual Compensation: $177.0K
Compensation as of Fiscal Year 2013.

oragenics inc (OGEN) Key Developments

Oragenics To Explore Strategic Alternatives For OTC Probiotic Products Business

The Board of Directors of Oragenics Inc. (AMEX:OGEN) has authorized the exploration of strategic alternatives with respect to the company’s over-the counter (‘OTC’) probiotic business. These alternatives could include joint ventures, strategic partnerships or alliances, a sale of the OTC probiotic products business or other possible transactions. Frederick Telling, Oragenics’ Chairman, said, “The board of directors and management team are committed to further enhancing value for all Oragenics shareholders. We believe it is a prudent time to explore strategic alternatives for this business unit as we concentrate and focus our efforts and resources on the ongoing collaborations we have with Intrexon Corporation for the development of our novel class of antibiotics known as lantibiotics and probiotics for treatment of diseases of the oral cavity.”

Oragenics Inc. Approves Change in Dr. Martin Handfield's Title from Vice President, Research and Development to Senior Vice President of Discovery Research

On December 5, 2014, Oragenics Inc. approved change in Dr. Dr. Martin Handfield's title from Vice President, Research and Development to Senior Vice President of Discovery Research.

Oragenics, Inc. Announces Resignation of John Bonfiglio as Chief Executive Officer, President and Director

Oragenics Inc. has announced that on October 30, 2014, Dr. John Bonfiglio resigned as Chief Executive Officer, President and director to pursue other opportunities. During the interim period before a new CEO is hired, the Board of Directors will provide direction to the company, with Dr. Frederick Telling acting as its liaison with management. Mr. Sullivan, the company's current CFO, will serve as the company's interim principal executive officer to address the vacancy created by Dr. Bonfiglio's resignation. The Board of Directors has begun the process of finding a permanent successor to Dr. Bonfiglio.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OGEN:US $1.15 USD +0.0017

OGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioGaia AB kr217.00 SEK +1.00
BLIS Technologies Ltd $0.02 NZD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation OGEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 34.4x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORAGENICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at